Apellis Pharmaceuticals APLS 深 滬
等待開盤 07-18 09:30:00 美东时间
20.04
+0.290
+1.47%
華盛通- 最 高20.605
- 今 開19.77
- 成交量 155.32万股
- 最 低 19.76
- 昨 收 19.75
- 總市值 25.25亿
- 52周最高 41.94
- 市盈率 靜 --
- 換手率 1.23%
- 52周最低 16.10
- 委 比 96.07%
- 總股本 1.26亿
- 歷史最高 94.75
- 量 比 0.99
- 振 幅 4.28%
- 歷史最低 11.45
- 每 手 1
- 風險率 7.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
Apellis Pharmaceuticals announced that five abstracts for SYFOVRE (pegcetacoplan injection) were accepted for oral presentation at the ASRS Annual Meeting. The data highlight SYFOVRE’s ability to slow geographic atrophy (GA) progression in AMD patients with just six annual doses. The presentations include insights on treatment efficacy, baseline characteristics, and long-term outcomes. SYFOVRE, the first approved therapy for GA, targets C3 to con...
07-15 11:00
Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Charles River Labs (CRL)
Companies in the Healthcare sector have received a lot of coverage today as ana...
07-09 18:20
大摩上调Apellis Pharmaceuticals(APLS.US)目标价至26美元 维持“持有”评级
摩根士丹利分析师Judah Frommer表示，这一评级是基于该公司市场地位及近期财务战略所作出的判断。
07-07 11:58
美股大行评级 | 潜在涨幅336.36%！Canaccord Genuity上调ATAI Life Sciences目标价至12美元，维持"买入"评级
Redburn Atlantic：下调Adobe(ADBE)评级至"卖出"，目标价从420美元降至280美元
07-03 11:01
Apellis Pharmaceuticals Announced A Capped Royalty Purchase Agreement With Sobi Under Which Apellis Will Receive Up To $300M In Exchange For 90% Of Apellis' Future Ex-U.S. Royalties For Aspaveli (Systemic Pegcetacoplan)
Under the companies' 2020 collaboration agreement, Apellis is eligible for tiered royalties on ex-U.S. sales of Aspaveli ranging from high teens to high twenties. Apellis retains exclusive commercialization rights for
07-01 19:09
Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)
Apellis Pharmaceuticals entered a capped royalty purchase agreement with Sobi®, receiving $275 million upfront and up to $25 million in milestone payments upon EMA approval for C3 glomerulopathy (C3G) and immune-complex membranoproliferative glomerulonephritis (IC-MPGN). The non-dilutive financing strengthens Apellis’ balance sheet and retains U.S. commercial rights for pegcetacoplan. The transaction reflects confidence in the drug’s growth poten...
07-01 11:00
Apellis phase 3 Empaveli data demonstrates sustained proteinuria reduction
New phase 3 data on Apellis Pharmaceuticals (NASDAQ:APLS) and Sobi's Empaveli (pegcetacoplan) indicated that the treatment led to proteinuria reduction that was sustained for a year. At week 26, ther...
06-06 23:39
Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN
Apellis Pharmaceuticals and Sobi presented new data from the Phase 3 VALIANT study showing that EMPAVELI (pegcetacoplan) achieved a significant 68% reduction in proteinuria versus placebo at Week 26 in patients with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), with results sustained at one year. EMPAVELI also stabilized kidney function as measured by eGFR. No new safety signals were observ...
06-06 13:15
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
Apellis Pharmaceuticals announced they will present at the Goldman Sachs 46th Annual Global Healthcare Conference on June 11, 2025. The live webcast will be available on their website, with a replay for 90 days post-event. The company specializes in developing C3-targeting therapies for serious diseases, including an approved treatment for geographic atrophy.
06-04 11:00
美股大行评级 | 再生元制药遭大摩下调评级，Aspen Insurance Hldgs(AHL)获多家机构首予“超配”评级！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1136585934532136961.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Vera Therapeutics(VERA)"买入"评级，目标价从75美元升至85美元</p> <p>• Ascendiant Capital：维持60 Degrees
06-03 09:06
